Endpoints News
Samsung Bio buys peptide manufacturer Read in browser
Endpoints News
Thank you for reading, dupa dupackia!
basic
UPGRADE
Mon T W Th F
20 July, 2026
sponsored by Biotech XYZ
Recruit NYC’s Top Biotech Talent at Biotech XYZ's Inaugural Career Fair
Biotech XYZ's Inaugural Career Fair offers a unique opportunity to connect with a targeted biotech talent pool from across NYC's life sciences community. Recruit for internship and full-time roles, access candidate resume books, increase brand visibility, and engage directly with future biotech leaders through employer booths and industry speaking opportunities.
Complete Interest Form
top stories
1. House lawmakers rally behind trade probe of China biotech market
2. Samsung Bio to expand its wheelhouse in $1.8B buy for peptide API maker
3. Unpacking Anthropic's 100-day sprint into biopharma: Nobel hires, M&A and major ambition
4. J&J, AbbVie said to have also looked at AtaiBeckley before Lilly’s $2.8B deal
5. Bristol Myers says it will build pharma's 'most powerful' AI supercomputer with Nvidia
more stories
 
Lydia Ramsey Pflanzer
.

It's not quite on the pharma beat, but the Cyclospora outbreak — and the false positive the FDA reported Sunday — have been on our minds.  The outbreak has been a big test for Acting Commissioner Kyle Diamantas, who previously oversaw the FDA food division.

.
Lydia Ramsey Pflanzer
Deputy Editor, Endpoints News
1
by Max Bayer

At least 10 House law­mak­ers are back­ing a US trade pan­el’s probe of Chi­na’s biotech sec­tor and re­lat­ed pric­ing prac­tices, en­cour­ag­ing fu­ture ex­ec­u­tive ac­tion.

In...

Read the full story
Manufacturing Day 2026
A year into the tariff era, the biopharma industry has stopped bracing for impact — however manufacturing and supply chain leaders are still rewriting their plans on the fly. We’re bringing together the experts tracking what R&D logistics looks like today. Join us — find out what’s next.
2
by Anna Brown

Sam­sung Bi­o­log­ics is set to branch in­to pep­tide in­gre­di­ent man­u­fac­tur­ing with plans to buy Swiss CD­MO PolyPep­tide for $1.8 bil­lion in cash.

The pur­chase, an­nounced...

Read the full story
Dario Amodei, co-founder and CEO of Anthropic (Jason Henry/Bloomberg via Getty Images)
3
by Andrew Dunn

A year ago, An­throp­ic’s life sci­ences plans were ba­si­cal­ly just a blog post by its CEO.

In late 2024, Dario Amod­ei wrote a 13,000-word memo...

Read the full story
4
by Kyle LaHucik

John­son & John­son and Ab­b­Vie, the two phar­ma gi­ants al­ready in the psy­che­del­ic space, al­so eyed AtaiBeck­ley, ac­cord­ing to a source fa­mil­iar with the sit­u­a­tion, but...

Read the full story
5
by Andrew Dunn

Bris­tol My­ers Squibb said Mon­day it will build "the most ad­vanced and en­er­gy-ef­fi­cient AI" su­per­com­put­er sys­tem in the bio­phar­ma in­dus­try, deep­en­ing its re­la­tion­ship with Nvidia...

Read the full story
Endpoints News
2029 Becker Drive; Lawrence, Kansas 66047 USA Privacy and deletion: help@endpointsnews.com
web twitter linkedin